Loading…
Barinthus Biotherapeutics plc is projected to rise to $0.6883 by 2027, a +8% move from its current price of $0.6378. BRNS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.6186 | $0.6382 | $0.6584 | +0.06% |
| Jul 13 | $0.611 | $0.6385 | $0.6673 | +0.11% |
| Jul 14 | $0.6053 | $0.6389 | $0.6743 | +0.17% |
| Jul 15 | $0.6006 | $0.6392 | $0.6803 | +0.22% |
| Jul 16 | $0.5965 | $0.6396 | $0.6858 | +0.28% |
| Jul 17 | $0.5929 | $0.64 | $0.6907 | +0.34% |
| Jul 18 | $0.5896 | $0.6403 | $0.6953 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5896 | $0.6403 | $0.6953 | +0.39% |
| Week 2 | $0.5721 | $0.6428 | $0.7223 | +0.79% |
| Week 3 | $0.5595 | $0.6454 | $0.7444 | +1.19% |
| Week 4 | $0.5494 | $0.6479 | $0.7641 | +1.58% |
| Week 5 | $0.5409 | $0.6505 | $0.7821 | +1.98% |
| Week 6 | $0.5336 | $0.653 | $0.7992 | +2.39% |
| Week 7 | $0.5271 | $0.6556 | $0.8154 | +2.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. It operates in the Healthcare sector.
The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection.
It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023.
Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Barinthus Biotherapeutics plc (BRNS) is a healthcare stock with a current price of $0.641 and a market capitalization of $26.18M. It is ranked 4821 by market size. The current price and market position place BRNS among smaller healthcare peers, with a multi-year forecast showing a path toward higher prices later in the horizon.
The forecast indicates a gradual upside over time, with the average price rising from $0.641 in 2026 to $3.73 by 2050 and the potential for a max of $7.76 in 2050. RoIs grow from modest levels in the near term to substantial gains in the distant years, culminating in a 481.6% max ROI by 2050, with bullish sentiment beginning in 2031.
A major floor 15.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.8% away) — a key level to hold.
The nearest ceiling, 13.5% above — a clean break opens room to run.
A major ceiling 19.9% above — clearing it would confirm fresh momentum.
Key BRNS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BRNS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6346 | Buy | $0.638 | Sell |
| MA 10 | $0.6455 | Sell | $0.6459 | Sell |
| MA 20 | $0.6678 | Sell | $0.6584 | Sell |
| MA 50 | $0.6736 | Sell | $0.6625 | Sell |
| MA 100 | $0.6347 | Buy | $0.6791 | Sell |
| MA 200 | $0.7818 | Sell | $0.7669 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.74 | Neutral |
| Stoch RSI (14) | 25.05 | Neutral |
| CCI (20) | -73.91 | Neutral |
| Williams %R (14) | -81.82 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -4.78 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 18.18 | Buy |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 38.01 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 0.63 | Buy |
| ADX (14) | 10.40 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is bearish. The RSI(14) sits at 40.
The simple moving averages show a gap to the downside: SMA50 at $0.6724 and SMA200 at $0.7951. Support is posted at $0.641 and resistance at $0.724. The recent 30-day range spans from $0.5038 to $0.8155, and annualized volatility stands at 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.54 | $0.6378 | $0.8812 | 0% | Neutral | |
| $0.5407 | $0.6883 | $0.9312 | +8% | Neutral | |
| $0.5537 | $0.728 | $1.03 | +14% | Neutral | |
| $0.5706 | $0.7706 | $1.12 | +21% | Bullish | |
| $0.5654 | $0.782 | $1.17 | +23% | Bullish | |
| $0.704 | $0.9952 | $1.52 | +56% | Bullish | |
| $0.7809 | $1.13 | $1.76 | +77% | Bullish | |
| $0.7948 | $1.17 | $1.86 | +83% | Bullish | |
| $0.849 | $1.27 | $2.06 | +99% | Bullish | |
| $0.7572 | $1.15 | $1.90 | +81% | Bullish | |
| $1.15 | $1.90 | $3.35 | +198% | Bullish | |
| $1.98 | $3.76 | $7.31 | +489% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.54 | $0.6378 | $0.7913 | +0.00% |
| August 2026 | $0.5642 | $0.6686 | $0.8155 | +4.83% |
| September 2026 | $0.562 | $0.6713 | $0.8291 | +0.41% |
| October 2026 | $0.5826 | $0.7008 | $0.8747 | +4.39% |
| November 2026 | $0.5914 | $0.7155 | $0.901 | +2.10% |
| December 2026 | $0.5706 | $0.6941 | $0.8812 | -2.99% |
Click any year to see its month-by-month BRNS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BRNS to range from $0.54 to $0.8812 through 2026. The $0.6378 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The BRNS price prediction for 2027 points to an average of $0.6883 (low $0.5407, high $0.9312) — a potential gain of +8% on today's $0.6378. A consolidation phase looks the most probable path here.
In 2028, BRNS is projected to trade between $0.5537 and $1.03, averaging $0.728 — a potential gain of +14% from today's $0.6378. That is up +6% on the projected 2027 average. Price action looks broadly range-bound.
Barinthus Biotherapeutics plc's 2029 outlook centres on $0.7706, within a $0.5706 to $1.12 range. That is up +6% on the projected 2028 average. That marks a +21% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, BRNS could reach as high as $1.17, with a base case around $0.782 and support toward $0.5654 — roughly +23% from $0.6378. Momentum favours further upside here.
Expect BRNS to range from $0.704 to $1.52 through 2031. The $0.9952 average target implies a +56% move from current prices. That is up +27% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The BRNS price prediction for 2032 points to an average of $1.13 (low $0.7809, high $1.76) — a potential gain of +77% on today's $0.6378. Momentum favours further upside here.
In 2033, BRNS is projected to trade between $0.7948 and $1.86, averaging $1.17 — a potential gain of +83% from today's $0.6378. That is up +4% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Barinthus Biotherapeutics plc's 2034 outlook centres on $1.27, within a $0.849 to $2.06 range. That is up +9% on the projected 2033 average. That marks a +99% change versus current levels. Momentum favours further upside here.
By 2035, BRNS could reach as high as $1.90, with a base case around $1.15 and support toward $0.7572 — roughly +81% from $0.6378. Buyers look set to stay in control over this stretch.
Expect BRNS to range from $1.15 to $3.35 through 2040. The $1.90 average target implies a +198% move from current prices. That is up +65% on the projected 2035 average. Momentum favours further upside here.
The BRNS price prediction for 2050 points to an average of $3.76 (low $1.98, high $7.31) — a potential gain of +489% on today's $0.6378. Buyers look set to stay in control over this stretch.
Investing $1,000 in BRNS today (≈ 1,567.889621 BRNS) could be worth
$5,888.42
+$4,888.42 (+489%) by 2050 · US Dollar
Based on the average projected BRNS price of $3.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BRNSwould be worth at today's price.
$1,000 invested in BRNS on Jul 10, 2025 (≈ 943.396277 BRNS) would be worth
$601.7
-$398.3 (-39.8%) today · 0.60× · US Dollar
Based on a BRNS entry price of $1.06 vs. today's $0.6378.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.62 | $1,028.71 | +2.9% |
| 1 month ago | $0.694 | $919.02 | -8.1% |
| 3 months ago | $0.568 | $1,122.89 | +12.3% |
| 6 months ago | $0.76 | $839.21 | -16.1% |
| 1 year ago | $1.06 | $601.7 | -39.8% |
| All time (5.0y) ago | $15.57 | $40.96 | -95.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BRNS forecast.
Our base-case forecast reaches $1.30 around 2040.
Implied market cap at $1.30: $53.1M
The multi-year forecast shows a shift from neutral to bullish sentiment starting in 2031, with a clear upside path in the following years. In 2030 the asset is forecast to average $0.7685, with a min of $0.5358 and a max of $1.19, yielding an expected ROI of 19.9%.
From 2031 onward, the model projects strong upside: 2031 avg $0.9858 with ROI 53.8% and 2032 avg $1.13 with ROI 76.4%; 2033 avg $1.18 with ROI 84%; and 2034 avg $1.25 with ROI 95.6%.
The bullish momentum extends further out, with 2040 avg $1.88 and a max of $3.52 yielding ROI 193.8%, and 2050 avg $3.73 with a max of $7.76 yielding ROI 481.6%. These longer-horizon numbers assume the progression reflected in the forecast and carry inherent uncertainty; they are estimates of potential outcomes, not guarantees.
Tap a question to reveal the answer.
2030: min $0.5358, avg $0.7685, max $1.19; ROI 19.9%; sentiment NEUTRAL.
The forecast shows upside in later years with 2031–2050 bull sentiment and higher max prices (e.g., 2031 avg $0.9858; 2050 max $7.76) but these are estimates, not guarantees.
2034 max is $2.13, with 2034 min $0.793 and avg $1.25, indicating a possible move above $2 within the forecast horizon.
Current price is $0.641 and market cap is $26.18M.
30-day range: $0.5038 to $0.8155; annualized volatility: 70%.
Barinthus Biotherapeutics plc Community Discussion
0Share your Barinthus Biotherapeutics plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.